Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-epitope HER2 peptide vaccine H2NVAC
- Development stage
- Phase 1
- Lead developer
- Mayo Clinic
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
H2NVAC is a multi-epitope T helper cell-activating peptide vaccine composed of four immunogenic epitopes derived from the tumor-associated antigen human epidermal growth factor receptor 2 (HER2). It is designed to stimulate specialized white blood cells, thereby increasing immune response and providing protection against breast cancer. The vaccine is admixed with GM-CSF as an adjuvant. Clinical trials have shown that H2NVAC generates robust, long-lasting T and B cell immune responses. Its primary indication is for the treatment of HER2-expressing ductal carcinoma in situ and residual disease after neoadjuvant chemotherapy in HER2-positive breast cancer[1][3][4][5].
- Other names
- multi-epitope HER2 peptide vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on multi-epitope HER2 peptide vaccine H2NVAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-epitope HER2 peptide vaccine H2NVAC.